Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Stereotactic body radiation therapy and surgery for early lung cancer "two sides of the same coin".

Parisi G, Ceschia T, Parisi A.

J Thorac Dis. 2019 Mar;11(Suppl 3):S271-S274. doi: 10.21037/jtd.2019.01.69. No abstract available.

2.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.

3.

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis.

Parisi A, Cortellini A, Cannita K, Bersanelli M, Ficorella C.

Case Rep Oncol Med. 2019 Feb 10;2019:3452762. doi: 10.1155/2019/3452762. eCollection 2019.

4.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

5.

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation.

Napoleoni L, Cortellini A, Cannita K, Parisi A, Dal Mas A, Calvisi G, Venditti O, Baldi PL, Cocciolone V, Ricci A, Ficorella C.

Bioengineering (Basel). 2019 Jan 22;6(1). pii: E11. doi: 10.3390/bioengineering6010011.

6.

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.

Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C, Cannita K, Parisi A, Brocco D, Tinari N, Ficorella C.

Thorac Cancer. 2019 Feb;10(2):347-351. doi: 10.1111/1759-7714.12965. Epub 2019 Jan 2.

7.

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C.

Oncol Lett. 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561. Epub 2018 Oct 10.

8.

Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab.

Cortellini A, Napoleoni L, Cimini N, Parisi A, Pavese F, DʼOrazio C, Verna L, Porzio G, Ficorella C.

J Clin Neuromuscul Dis. 2018 Dec;20(2):99-100. doi: 10.1097/CND.0000000000000220. No abstract available.

PMID:
30439756
9.

Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.

Cortellini A, Palumbo P, Porzio G, Verna L, Giordano AV, Masciocchi C, Parisi A, Cannita K, Ficorella C, Bozzetti F.

Thorac Cancer. 2018 Dec;9(12):1623-1630. doi: 10.1111/1759-7714.12870. Epub 2018 Sep 27.

10.

Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients.

Rastrelli M, Ferrazzi B, Cavallin F, Chiarion Sileni V, Pigozzo J, Fabozzi A, Tropea S, Vecchiato A, Costa A, Parisi A, Rossi CR, Del Fiore P, Alaibac M.

Cancers (Basel). 2018 Sep 24;10(10). pii: E350. doi: 10.3390/cancers10100350.

11.

Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

Cortellini A, Dal Mas A, Cannita K, Collina G, Parisi A, Pavese F, Porzio G, Verna L, Ficorella C.

J Thorac Dis. 2018 Jul;10(7):E520-E525. doi: 10.21037/jtd.2018.06.44. No abstract available.

12.

Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.

Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B, Vicentini R, Vicentini V, Verna L, Porzio G, Ficorella C.

Oncol Rep. 2018 Aug;40(2):803-812. doi: 10.3892/or.2018.6475. Epub 2018 Jun 6.

PMID:
29901103
13.

Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study.

Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group.

Health Qual Life Outcomes. 2018 Jun 13;16(1):122. doi: 10.1186/s12955-018-0952-5.

14.

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study.

Cortellini A, Porzio G, Masel EK, Berghoff AS, Knotzer B, Parisi A, Pavese F, Ficorella C, Verna L.

Palliat Support Care. 2019 Feb;17(1):82-86. doi: 10.1017/S1478951518000238. Epub 2018 May 24.

PMID:
29792235
15.

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.

Cortellini A, Parisi A, Fargnoli MC, Cannita K, Irelli A, Porzio G, Martinazzo C, Ficorella C.

Case Rep Oncol Med. 2018 Mar 8;2018:2783917. doi: 10.1155/2018/2783917. eCollection 2018.

16.

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.

Cortellini A, Bersanelli M, Buti S, Gambale E, Atzori F, Zoratto F, Parisi A, Brocco D, Pireddu A, Cannita K, Iacono D, Migliorino MR, Gamucci T, De Tursi M, Sidoni T, Tiseo M, Michiara M, Papa A, Angius G, Tomao S, Fargnoli MC, Natoli C, Ficorella C.

Immunotherapy. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167. Epub 2018 Mar 22.

17.

Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.

Cortellini A, Gambale E, Cannita K, Brocco D, Parisi A, Napoleoni L, Masedu F, Irtelli L, De Tursi M, Natoli C, Ficorella C.

Thorac Cancer. 2018 Feb;9(2):241-252. doi: 10.1111/1759-7714.12570. Epub 2017 Dec 7.

18.

The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes.

Watutantrige-Fernando S, Vianello F, Barollo S, Bertazza L, Galuppini F, Cavedon E, Censi S, Benna C, Ide EC, Parisi A, Nacamulli D, Iacobone M, Pennelli G, Mian C.

Thyroid. 2018 Jan;28(1):96-103. doi: 10.1089/thy.2017.0248. Epub 2018 Jan 2.

PMID:
29179638
19.

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy.

Cortellini A, Verna L, Cannita K, Napoleoni L, Parisi A, Ficorella C, Porzio G.

Indian J Palliat Care. 2017 Jul-Sep;23(3):350-352. doi: 10.4103/IJPC.IJPC_23_17.

20.

Pros-IT CNR: an Italian prostate cancer monitoring project.

Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group.

Aging Clin Exp Res. 2017 Apr;29(2):165-172. doi: 10.1007/s40520-017-0735-6. Epub 2017 Feb 24.

PMID:
28236267

Supplemental Content

Loading ...
Support Center